An ever increasing demand for new lead compounds in the pharmaceutical industry has led scientists to search for natural bioactive products. Based on this extensive research, marine invertebrates now represent a rich source of novel substances with significant anti-neoplastic activities. As the current approach of synthesizing new and chemically modifying old drugs seems to have slowed down, and the identification of new anticancer drugs is not too promising, a new approach is clearly needed. The objective of this review is to present up-to-date data on these newer compounds. Based on the data summarized in this short review, it is clear that marine invertebrates represent an extremely important source of compounds with potential anti-cancer effects. Considering that we tested only a tiny number of Porifera and Coelenterata, the best is yet to come.

Peter Sima Institute of Microbiology Czech Academy of Sciences 142 20 Prague 15400 Czech Republic

Zobrazit více v PubMed

Hughes AL, Yeager M. Molecular evolution of the vertebrate immune system. Bioessays. 1997;19:777–786. PubMed

Zapata A, Amemiya CT. Phylogeny of lower vertebrates and their immunological structures. Curr Top Microbiol Immunol. 2000;248:67–107. PubMed

Rosenthal J. Investing in biological diversity. Proc Cairns Conf; Cairns: OECD;; 1996. pp. 1–56.

Pomponi SA. The bioprocess-technological potential of the sea. J Biotechnol. 1999;70:5–13.

Jimeno JM. A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs. 2002;13 Suppl 1:S15–S19. PubMed

De Bary AH. Die erscheinung der symbiose. Cassel: Naturforsch Versamml; 1869. pp. 1–103.

Williams DH, Stone MJ, Hauck PR, Rahman SK. Why are secondary metabolites (natural products) biosynthesized. J Nat Prod. 1989;52:1189–1208. PubMed

Šima P, Trebichavsky I, Sigler K. Non-mammalian antibiotic peptides. F. olia Microbiol. 2003;48:709–724. PubMed

Donia M, Hamann MT. Marine natural products and their potential applications as anti-infective agents. Lancet Infect Dis. 2003;3:338–348. PubMed PMC

Nagle DG, Zhou Y-D. Marine Natural Products as Inhibitors of Hypoxic Signaling in Tumors. Phytochem Rev. 2009;8:415–429. PubMed PMC

Kinghorn AD, Drug discovery from natural products. In: Lemke TL, Williams DA, editors, Foye’s Principles of Medicinal Chemistry. 6th ed. Philadelphia: Wolters Kluwer/Williams and Wilkins; 2008. pp. 12–25.

Mayer AM, Gustafson KR. Marine pharmacology in 2000: antitumor and cytotoxic compounds. Int J Cancer. 2003;105:291–299. PubMed

Amador ML, Jimeno J, Paz-Ares L, Cortes-Funes H, Hidalgo M. Progress in the development and acquisition of anticancer agents from marine sources. Ann Oncol. 2003;14:1607–1615. PubMed

Blunt JW, Copp BR, Hu WP, Munro MH, Northcote PT, Prinsep MR. Marine natural products. Nat Prod Rep. 2009;26:170–244. PubMed

Munro MHG, Blunt JW, Lake RJ, Litaudon M, Battershill CN, Page MJ. From seabed to sickbed: What are the prospects. In: Van Soest RWM, van Kempen TMG, Braekman JC., editors. Sponges in time and space. Rotterdam: A.A. Balkema; 1994. pp. 473–484.

Pomponi SA, Willoughby R. Sponge cell culture for production of bioactive metabolites. In: Van Soest RWM, van Kempen TMG, Braekman JC., editors. Sponges in time and space. Rotterdam: A.A. Balkema; 1994. pp. 395–400.

Thoms C, Schupp PJ. Biotechnological potential of marine sponges and their associated bacteria as producers of new pharmaceuticals (Part I) J Internat Biotechnol Law. 2005;2:217–220.

Thoms C, Schupp PJ. Biotechnological potential of marine sponges and their associated bacteria as producers of new pharmaceuticals (Part II) J Internat Biotechnol Law. 2005;2:257–264.

Bewley CA, Faulkner DJ. Lithistid sponges: Star performers or hosts to the stars. Angewandte Chemie International Edit. 1998;37:2162–2178. PubMed

Schmidt EW, Obraztsova AY, Davidson SK, Faulkner DJ, Haygood MG. Identification of theantifungal peptide-containing symbiont of the marine sponge T. swinhoei as a novel deltaproteobacterium, “Candidatus Entotheonella palauensis”. Mar Biol. 2000;136:969–977.

Burja AM, Hill RT. Microbial symbionts of the Australian Great Barrier Reef sponge, Candidaspongia flabellata. Hydrobiologia. 2001;461:41–47.

Schupp PJ, Kohlert-Scupp C, Whitefield S, Engemann A, Rohde S, Hemscheldt T, Pezzuto JM. Cancer chemopreventive and anticancer evaluation of extracts and fractions from marine macro- and micro-organisms collected from twilight zone waters around Guam. Nat Prod Comm. 2009;4:1717–1728. PubMed PMC

Penesyan A, Kjelleberg S, Egan S. Development of novel drugs from marine surface associated microorganisms. Mar Drugs. 2010;8:438–459. PubMed PMC

Berquist PR. Sponges. Berkeley: University of California Press; 1978.

Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH. Marine sponges as pharmacy. Mar Biotechnol (NY) 2005;7:142–162. PubMed PMC

Proksch P. Defensive roles for secondary metabolites from marine sponges and sponge-feeding nudibranchs. Toxicon. 1994;32:639–655. PubMed

Větvička V, Šima P. Evolutionary mechanism of defense reactions. Berlin: Birkhauser Verlag; 1998. pp. 1–196.

Fusetani N, Kem W. Marine toxins: an overview. Prog Mol Subcell Biol. 2009;46:1–44. PubMed

Kikuchi A, Nieda M, Schmidt C, Koezuka Y, Ishihara S, Ishikawa Y, Tadokoro K, Durrant S, Boyd A, Juji T, et al. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Br J Cancer. 2001;85:741–746. PubMed PMC

Tan G, Gyllenhaal C, Soejarto DD. Biodiversity as a source of anticancer drugs. Curr Drug Targets. 2006;7:265–277. PubMed

Zhang W, Guo YW, Gu Y. Secondary metabolites from the South China Sea invertebrates: chemistry and biological activity. Curr Med Chem. 2006;13:2041–2090. PubMed

Shen YC, Prakash CV. Two new acetylenic derivatives and a new meroditerpenoid from a Taiwanese marine sponge Strongylophora durissima. J Nat Prod. 2000;63:1686–1688. PubMed

Wright AE, Botelho JC, Guzmán E, Harmody D, Linley P, McCarthy PJ, Pitts TP, Pomponi SA, Reed JK. Neopeltolide, a macrolide from a lithistid sponge of the family Neopeltidae. J Nat Prod. 2007;70:412–416. PubMed

Youngsaye W, Lowe JT, Pohlki F, Ralifo P, Panek JS. Total synthesis and stereochemical reassignment of (+)-neopeltolide. Angew Chem Int Ed Engl. 2007;46:9211–9214. PubMed

Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents. 2005;5:65–71. PubMed

Miller JH, Singh AJ, Northcote PT. Microtubule-stabilizing drugs from marine sponges: focus on peloruside A and zampanolide. Mar Drugs. 2010;8:1059–1079. PubMed PMC

Kingston DG. Tubulin-interactive natural products as anticancer agents. J Nat Prod. 2009;72:507–515. PubMed PMC

Saito SY. Toxins affecting actin filaments and microtubules. Prog Mol Subcell Biol. 2009;46:187–219. PubMed

Urban S, Hobbs L, Hooper JNA, Capon RJ, Lamellarins Q an R: new aromatic metabolites from Australian marine sponge Dendrilla cactos. Aust J Chem. 1995;48:1491–1494.

Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol. 1992;12:5447–5454. PubMed PMC

Ebada SS, Lin W, Proksch P. Bioactive sesterterpenes and triterpenes from marine sponges: occurrence and pharmacological significance. Mar Drugs. 2010;8:313–346. PubMed PMC

Bergmann W, Johnson TB. The chemistry of marine animals.I. The sponge Microciona pralifera. Z Physiol Chem. 1933;222:220–226.

Ravi BN, Wells RJ, Croft KD. Malabaricane triterpenes from a Fijian collection of the sponge Jaspis stellifera. J Org Chem. 1981;46:1998–2001.

Zhang WH, Che CT. Isomalabaricane-type nortriterpenoids and other constituents of the marine sponge Geodia japonica. J Nat Prod. 2001;64:1489–1492. PubMed

Lv F, Deng Z, Li J, Fu H, van Soest RW, Proksch P, Lin W. Isomalabaricane-type compounds from the marine sponge Rhabdastrella aff. distincta. J Nat Prod. 2004;67:2033–2036. PubMed

Gordaliza M. Terpenyl-purines from the sea. Mar Drugs. 2009;7:833–849. PubMed PMC

Kumar D, Rawat DS. 7. Marine natural alkaloids as anticancer agents. Opp Challenge Scope Nat Prod Med Chem. 2001;37:213–268.

Jiang B, Smallheer JM, Amaral-Ly C, Wuonola MA. Total synthesis of (±) Dragmacidin: A cytotoxic bis(indole)alkaloid of marine origin. J Org Chem. 1994;59:6823–6827.

Burres NS, Barber DA, Gunasekera SP, Shen LL, Clement JJ. Antitumor activity and biochemical effects of topsentin. Biochem Pharmacol. 1991;42:745–751. PubMed PMC

Endo T, Tsuda M, Fromont J, Kobayashi J. Hyrtinadine A, a bis-indole alkaloid from a marine sponge. J Nat Prod. 2007;70:423–424. PubMed

Samoylenko V, Khan SI, Jacoba MR, Tekwani BL, Walker LA, Hufford CD, Muhammad I. Bioactive (+)-manzamine A and (+)-8-hydroxymanzamine A tertiary bases and salts from Acanthostrongylophora ingens and their preparations. Nat Prod Commun. 2009;4:185–192. PubMed PMC

Kuramoto M, Miyake N, Ishimaru Y, Ono N, Uno H. Cylindradines A and B: novel bromopyrrole alkaloids from the marine sponge Axinella cylindratus. Org Lett. 2008;10:5465–5468. PubMed

Mason C, McFarlane S, Johynson PG, Crowe P, Erwin PJ, Domostoj MM, Campbell FC, Manaviazar S, Hale KJ, El-Tanadi M. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Canc Therapeut. 2008;7:548–558. PubMed

Zöllinger M, Kelter G, Fiebig HH, Lindel T. Antitumor activity of the marine natural product dibromophakellstatin in vitro. Bioorg Med Chem Lett. 2007;17:346–349. PubMed

Laport MS, Santos OC, Muricy G. Marine sponges: potential sources of new antimicrobial drugs. Curr Pharm Biotechnol. 2009;10:86–105. PubMed

Barnes RD. Invertebrate Zoology. Philadelphia: Saunders College Publishing; 1987.

Iwashima M, Matsumoto Y, Takenaka Y, Iguchi K, Yamori T. A new marin B, novel diterpenoidic alcohols esterified by (E)-N(1)-methylurocanic acid. Isolation from the Mediterranean stolonifer Sarcodictyon roseum. Helv Chim Acta. 1987;70:2019–2027.

Su JH, Wen ZH. Bioactive cembrane-based diterpenoids from the soft coral Sinularia triangular. Mar Drugs. 2011;9:944–951. PubMed PMC

Duh CY, Wang SK, Chu MJ, Sheu JH. Cytotoxic sterols from the soft coral Nephthea erecta. J Nat Prod. 1998;61:1022–1024. PubMed

Lindel T, Jensen PR, Fenical W, Long BH, Casazza AM, Carboni J, Fairchild CR. Eleutherobin, a new cytotoxin that mimics paclitaxel (Taxol) by stabilizing microtubules. J Am Chem Soc. 1997;119:8744–8745.

Long BH, Carboni JM, Wasserman AJ, Cornell LA, Casazza AM, Jensen PR, Lindel T, Fenical W, Fairchild CR. Eleutherobin, a novel cytotoxic agent that induces tubulin polymerization, is similar to paclitaxel (Taxol) Cancer Res. 1998;58:1111–1115. PubMed

Burres NS, Barber DA, Gunasekera SP, Shen LL, Clement JJ. Antitumor activity and biochemical effects of topsentin. Biochem Pharmacol. 1991;42:745–751. PubMed PMC

Hamel E, Sackett DL, Vourloumis D, Nicolaou KC. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site. Biochemistry. 1999;38:5490–5498. PubMed

McDaid HM, Bhattacharya SK, Chen XT, He L, Shen HJ, Gutteridge CE, Horwitz SB, Danishefsky SJ. Structure-activity profiles of eleutherobin analogs and their cross-resistance in Taxol-resistant cell lines. Cancer Chemother Pharmacol. 1999;44:131–137. PubMed

Li L, Wang CY, Huang H, Mollo E, Cimino G, Guo YW. Further highly oxygenated guaiane lactones from the South Sea gorgonian Menella sp. Helv Chim Acta. 2008;91:111–117.

Park HW, Choi SU, Baek NI, Kim SH, Eun JS, Yang JH, Kim DK. Guaiane sesquiterpenoids from Torilis japonica and their cytotoxic effects on human cancer cell lines. Arch Pharm Res. 2006;29:131–134. PubMed

Molinski TF, Dalisay DS, Lievens SL, Saludes JP. Drug development from marine natural products. Nat Rev Drug Discov. 2009;8:69–85. PubMed